BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30683066)

  • 1. Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review.
    Imakita T; Matsumoto H; Hirano K; Morisawa T; Sakurai A; Kataoka Y
    BMC Cancer; 2019 Jan; 19(1):105. PubMed ID: 30683066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Analysis of the Efficacy of Rebiopsy and
    Hong MH; Kim HR; Ahn BC; Heo SJ; Kim JH; Cho BC
    Yonsei Med J; 2019 Jun; 60(6):525-534. PubMed ID: 31124335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
    Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
    Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.
    Kawamura T; Kenmotsu H; Taira T; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Nakajima T; Ohde Y; Endo M; Takahashi T
    Cancer Sci; 2016 Jul; 107(7):1001-5. PubMed ID: 27145431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.
    Koo HJ; Kim MY; Park S; Lee HN; Kim HJ; Lee JC; Kim SW; Lee DH; Choi CM
    Radiology; 2018 Oct; 289(1):227-237. PubMed ID: 30015588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI.
    Chiang CL; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH
    Target Oncol; 2020 Aug; 15(4):503-512. PubMed ID: 32696212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
    Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170
    [No Abstract]   [Full Text] [Related]  

  • 8. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
    Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Nanjo S; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
    Cancer; 2013 Dec; 119(24):4325-32. PubMed ID: 24105277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When compared to plasma-based detection, osimertinib-treated non-small cell lung cancer (NSCLC) with tissue rebiopsy-confirmed acquired T790M mutation is associated with better survival.
    Kwok WC; Ho JCM; Lam DCL; Lui MMS; Ip MSM; Tam TCC
    Asia Pac J Clin Oncol; 2021 Apr; 17(2):e35-e39. PubMed ID: 31802642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rebiopsy methods and clinical features on T790M mutation after first-line EGFR-TKI treatment failure.
    Zhou J; Li Y; Zhang Y; Dai H; Guo S
    Future Oncol; 2021 Jul; 17(19):2475-2488. PubMed ID: 33769072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
    Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M
    Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial).
    Usui K; Yokoyama T; Naka G; Ishida H; Kishi K; Uemura K; Ohashi Y; Kunitoh H
    Jpn J Clin Oncol; 2019 Jun; 49(6):554-558. PubMed ID: 30809659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment.
    Tseng JS; Yang TY; Chen KC; Hsu KH; Huang YH; Su KY; Yu SL; Chang GC
    Cancer Res Treat; 2018 Oct; 50(4):1164-1174. PubMed ID: 29228521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
    Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
    Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.
    Bollinger MK; Agnew AS; Mascara GP
    J Oncol Pharm Pract; 2018 Jul; 24(5):379-388. PubMed ID: 28565936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.
    Joo JW; Hong MH; Shim HS
    Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study.
    Kudo K; Nishii K; Makimoto G; Ishikawa N; Tsubata Y; Kodani M; Fujimoto N; Yamasaki M; Kubota T; Takigawa N; Fujitaka K; Kanaji N; Shibayama T; Itano J; Ando C; Hotta K; Kiura K
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):1869-1877. PubMed ID: 35386002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.